CROSS COUNTRY HEALTHCARE INC (CCRN) Stock Fundamental Analysis
USA - NASDAQ:CCRN - US2274831047 - Common Stock
13.14 USD
+0.52 (+4.12%)
13.14 USD
0 (0%)
Overall CCRN gets a fundamental rating of 5 out of 10. We evaluated CCRN against 101 industry peers in the Health Care Providers & Services industry. CCRN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. CCRN does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
CCRN had positive earnings in the past year.
CCRN had a positive operating cash flow in the past year.
In multiple years CCRN reported negative net income over the last 5 years.
Of the past 5 years CCRN 4 years had a positive operating cash flow.
1.2 Ratios
CCRN's Return On Assets of -1.51% is in line compared to the rest of the industry. CCRN outperforms 42.57% of its industry peers.
CCRN has a Return On Equity (-2.02%) which is comparable to the rest of the industry.
CCRN has a Return On Invested Capital (1.44%) which is comparable to the rest of the industry.
The Average Return On Invested Capital over the past 3 years for CCRN is significantly above the industry average of 9.33%.
The last Return On Invested Capital (1.44%) for CCRN is well below the 3 year average (15.05%), which needs to be investigated, but indicates that CCRN had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.51% | ||
| ROE | -2.02% | ||
| ROIC | 1.44% |
ROA(3y)9.37%
ROA(5y)8.5%
ROE(3y)17.7%
ROE(5y)17.81%
ROIC(3y)15.05%
ROIC(5y)13.58%
1.3 Margins
The Operating Margin of CCRN (0.78%) is comparable to the rest of the industry.
CCRN's Operating Margin has declined in the last couple of years.
CCRN has a Gross Margin (20.19%) which is in line with its industry peers.
In the last couple of years the Gross Margin of CCRN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.78% | ||
| PM (TTM) | N/A | ||
| GM | 20.19% |
OM growth 3Y-77.97%
OM growth 5Y-33.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.01%
GM growth 5Y-3.83%
2. Health
2.1 Basic Checks
CCRN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, CCRN has less shares outstanding
Compared to 5 years ago, CCRN has less shares outstanding
CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CCRN has an Altman-Z score of 4.96. This indicates that CCRN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CCRN (4.96) is better than 82.18% of its industry peers.
CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.96 |
ROIC/WACC0.17
WACC8.66%
2.3 Liquidity
CCRN has a Current Ratio of 3.21. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.21, CCRN belongs to the top of the industry, outperforming 85.15% of the companies in the same industry.
A Quick Ratio of 3.21 indicates that CCRN has no problem at all paying its short term obligations.
CCRN has a better Quick ratio (3.21) than 86.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.21 | ||
| Quick Ratio | 3.21 |
3. Growth
3.1 Past
CCRN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -78.35%.
CCRN shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 24.57% yearly.
Looking at the last year, CCRN shows a very negative growth in Revenue. The Revenue has decreased by -24.30% in the last year.
The Revenue has been growing by 10.33% on average over the past years. This is quite good.
EPS 1Y (TTM)-78.35%
EPS 3Y-47.22%
EPS 5Y24.57%
EPS Q2Q%-110%
Revenue 1Y (TTM)-24.3%
Revenue growth 3Y-7.11%
Revenue growth 5Y10.33%
Sales Q2Q%-19.34%
3.2 Future
The Earnings Per Share is expected to decrease by -16.16% on average over the next years. This is quite bad
Based on estimates for the next years, CCRN will show a decrease in Revenue. The Revenue will decrease by -5.63% on average per year.
EPS Next Y-68.27%
EPS Next 2Y-21.05%
EPS Next 3Y-16.16%
EPS Next 5YN/A
Revenue Next Year-16.68%
Revenue Next 2Y-8.76%
Revenue Next 3Y-5.63%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CCRN is valuated quite expensively with a Price/Earnings ratio of 62.57.
The rest of the industry has a similar Price/Earnings ratio as CCRN.
Compared to an average S&P500 Price/Earnings ratio of 27.69, CCRN is valued quite expensively.
CCRN is valuated quite expensively with a Price/Forward Earnings ratio of 46.84.
CCRN's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of CCRN to the average of the S&P500 Index (23.18), we can say CCRN is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 62.57 | ||
| Fwd PE | 46.84 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CCRN is valued a bit cheaper than 63.37% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CCRN is valued cheaply inside the industry as 85.15% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.63 | ||
| EV/EBITDA | 12.28 |
4.3 Compensation for Growth
A cheap valuation may be justified as CCRN's earnings are expected to decrease with -16.16% in the coming years.
PEG (NY)N/A
PEG (5Y)2.55
EPS Next 2Y-21.05%
EPS Next 3Y-16.16%
5. Dividend
5.1 Amount
No dividends for CCRN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
13.14
+0.52 (+4.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners98.83%
Inst Owner Change0.01%
Ins Owners5.37%
Ins Owner Change-0.41%
Market Cap430.47M
Analysts52.31
Price Target18.44 (40.33%)
Short Float %7.52%
Short Ratio6.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-56.4%
Min EPS beat(2)-118.38%
Max EPS beat(2)5.59%
EPS beat(4)2
Avg EPS beat(4)-39.17%
Min EPS beat(4)-118.38%
Max EPS beat(4)22.23%
EPS beat(8)4
Avg EPS beat(8)-22%
EPS beat(12)8
Avg EPS beat(12)-10.41%
EPS beat(16)12
Avg EPS beat(16)-0.77%
Revenue beat(2)0
Avg Revenue beat(2)-6.65%
Min Revenue beat(2)-7.46%
Max Revenue beat(2)-5.84%
Revenue beat(4)0
Avg Revenue beat(4)-3.61%
Min Revenue beat(4)-7.46%
Max Revenue beat(4)-0.41%
Revenue beat(8)1
Avg Revenue beat(8)-2.19%
Revenue beat(12)4
Avg Revenue beat(12)-0.89%
Revenue beat(16)7
Avg Revenue beat(16)0.6%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-52.46%
EPS NY rev (1m)0%
EPS NY rev (3m)-54.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 62.57 | ||
| Fwd PE | 46.84 | ||
| P/S | 0.36 | ||
| P/FCF | 12.63 | ||
| P/OCF | 10.35 | ||
| P/B | 1.04 | ||
| P/tB | 1.8 | ||
| EV/EBITDA | 12.28 |
EPS(TTM)0.21
EY1.6%
EPS(NY)0.28
Fwd EY2.13%
FCF(TTM)1.04
FCFY7.92%
OCF(TTM)1.27
OCFY9.66%
SpS36.4
BVpS12.58
TBVpS7.31
PEG (NY)N/A
PEG (5Y)2.55
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.51% | ||
| ROE | -2.02% | ||
| ROCE | 2.04% | ||
| ROIC | 1.44% | ||
| ROICexc | 1.75% | ||
| ROICexgc | 3.24% | ||
| OM | 0.78% | ||
| PM (TTM) | N/A | ||
| GM | 20.19% | ||
| FCFM | 2.86% |
ROA(3y)9.37%
ROA(5y)8.5%
ROE(3y)17.7%
ROE(5y)17.81%
ROIC(3y)15.05%
ROIC(5y)13.58%
ROICexc(3y)15.28%
ROICexc(5y)13.73%
ROICexgc(3y)22.9%
ROICexgc(5y)20.79%
ROCE(3y)21.31%
ROCE(5y)19.23%
ROICexcg growth 3Y-75.41%
ROICexcg growth 5Y-32.32%
ROICexc growth 3Y-77.25%
ROICexc growth 5Y-30.83%
OM growth 3Y-77.97%
OM growth 5Y-33.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.01%
GM growth 5Y-3.83%
F-Score5
Asset Turnover2.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 42.39% | ||
| Cap/Sales | 0.63% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 153.74% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.21 | ||
| Quick Ratio | 3.21 | ||
| Altman-Z | 4.96 |
F-Score5
WACC8.66%
ROIC/WACC0.17
Cap/Depr(3y)64.63%
Cap/Depr(5y)60.57%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-78.35%
EPS 3Y-47.22%
EPS 5Y24.57%
EPS Q2Q%-110%
EPS Next Y-68.27%
EPS Next 2Y-21.05%
EPS Next 3Y-16.16%
EPS Next 5YN/A
Revenue 1Y (TTM)-24.3%
Revenue growth 3Y-7.11%
Revenue growth 5Y10.33%
Sales Q2Q%-19.34%
Revenue Next Year-16.68%
Revenue Next 2Y-8.76%
Revenue Next 3Y-5.63%
Revenue Next 5YN/A
EBIT growth 1Y-69.02%
EBIT growth 3Y-79.54%
EBIT growth 5Y-27.01%
EBIT Next Year540.8%
EBIT Next 3Y89.71%
EBIT Next 5YN/A
FCF growth 1Y-88.57%
FCF growth 3YN/A
FCF growth 5Y112.02%
OCF growth 1Y-86.63%
OCF growth 3YN/A
OCF growth 5Y85.29%